Ciprofloxacin HCL 500 MG tab 100S
Ended Awarded
- Contract number
- SPE2DB26FKXVS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,680
Award facts
- Contract value 100% obligated
- $1,680.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $1,680.15 to DMS Pharmaceutical Group Inc. for the supply of Ciprofloxacin HCl 500 mg tablets (100 count) on October 30, 2025, with an ultimate completion date of October 31, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order will be performed at the company's Park Ridge facility and represents one of numerous purchases issued to the vendor by the DLA's Medical Supply Chain division to support Department of Defense pharmaceutical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The IDC authorizes DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support military healthcare facilities worldwide. No subcontractor relationships have been identified in the award documentation.
Quick answers
Who was awarded contract SPE2DB26FKXVS?
SPE2DB26FKXVS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DB26FKXVS worth?
The government has obligated $1,680 on SPE2DB26FKXVS.
Is contract SPE2DB26FKXVS an order under another contract?
Yes. SPE2DB26FKXVS is a delivery order under SPE2DB24D9801, an indefinite delivery contract.
Was contract SPE2DB26FKXVS competed?
The extent of competition for SPE2DB26FKXVS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award